Cargando…
Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer’s Disease Clinical Spectrum: A Population-Based Study
BACKGROUND: Plasma biomarkers have emerged as a promising approach for characterizing pathophysiology in mild cognitive impairment (MCI) and Alzheimer’s disease (AD). OBJECTIVE: We aimed to characterize plasma biomarkers for AD and neurodegeneration across the AD clinical continuum, and to assess th...
Autores principales: | Dong, Yi, Hou, Tingting, Li, Yuanjing, Liu, Rui, Cong, Lin, Liu, Keke, Liu, Cuicui, Han, Xiaolei, Ren, Yifei, Tang, Shi, Winblad, Bengt, Blennow, Kaj, Wang, Yongxiang, Du, Yifeng, Qiu, Chengxuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657676/ https://www.ncbi.nlm.nih.gov/pubmed/37899059 http://dx.doi.org/10.3233/JAD-230932 |
Ejemplares similares
-
Objectively-measured movement behaviors, systemic low-grade inflammation, and plasma neurofilament light chain in older adults: a population-based study
por: Wang, Yongxiang, et al.
Publicado: (2023) -
KIBRA regulates amyloid β metabolism by controlling extracellular vesicles secretion
por: Han, Xiaolei, et al.
Publicado: (2022) -
Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies
por: Kmezic, Ivan, et al.
Publicado: (2022) -
Neurofilament light and tau as blood biomarkers for sports-related concussion
por: Shahim, Pashtun, et al.
Publicado: (2018) -
Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?
por: Niemelä, Valter, et al.
Publicado: (2017)